ICML 2025 | Early activity of ELA026, a pan-SIRP antibody, in patients with T-cell lymphoma

Yeah, ELA026 is an antibody that targets SIRP-alpha, beta, and gamma. So it’s a pan-SIRP antibody, unlike the magrolimab and unlike the MAPLE that is also under study. So it targets a pan-SIRP and by doing that it depletes macrophages, activated T-cells, and it’s very important in a condition like HLH which is caused by hyperactivation of T-cells, macrophages, and cytokines, so this triad, the trifecta, creates that storm, the perfect storm, if you will, and there are no therapies; outcomes are very poor, the mortality rate is about 70% in two months, so it’s very, very poor outcomes in this population, and this group of patients. ELA026, to study, we had a late-breaking abstract last year, at ASH, what we’re presenting this time is this, the kind of patients that are enrolled, there are about 40 patients enrolled, majority of them are T-cell lymphoma patients, and we found that the T-cell lymphoma patients, when they were treated for HLH, not only did the HLH have a response, a positive response of PR or CR, but they also had a complete remission of the T-cell lymphoma, so we have about six patients with long-term responses. A classic case in point, this was a patient with cytotoxic T-cell lymphoma with spleen all the way to the pelvis, 27 centimeters. After 12 weeks of therapy, is in remission. So we think that there’s also a signal in the T-cell lymphomas where they deplete the malignant T-cells in addition to the activated T-cells.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.